{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:49:22Z","timestamp":1782272962202,"version":"3.54.5"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eururo.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:37:11Z","timestamp":1782272231000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men with Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)"],"prefix":"10.1016","author":[{"given":"Hongzhi","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.06.001_b0005","doi-asserted-by":"crossref","unstructured":"McKay RR, Xie W, Ajmera A, et al. Multicenter, randomized, phase II trial of olaparib plus radium-223 versus radium-223 in men with castration-resistant prostate cancer with bone metastases (COMRADE). J Clin Oncol. In press. https:\/\/doi.org\/10.1200\/JCO-25-02835.","DOI":"10.1200\/JCO-25-02835"},{"key":"10.1016\/j.eururo.2026.06.001_b0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.euo.2024.07.007","article-title":"Clinical, imaging, and technical factors associated with successful genomic profiling of bone biopsy tissue in prostate cancer","volume":"8","author":"Ridouani","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.06.001_b0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamaoncol.2020.5161","article-title":"Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference","volume":"7","author":"Jensen","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.06.001_b0020","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","article-title":"Elucidating acquired PARP inhibitor resistance in advanced prostate cancer","volume":"42","author":"Seed","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2026.06.001_b0025","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.eururo.2024.12.007","article-title":"Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: a living interactive systematic review and meta-analysis","volume":"87","author":"Naqvi","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.001_b0030","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.2967\/jnumed.124.267899","article-title":"[68Ga]Ga-PSMA-11 PET and prostate cancer bone metastases: diagnostic performance of available standardized criteria","volume":"65","author":"Mainta","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.001_b0035","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41391-022-00569-8","article-title":"Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy","volume":"26","author":"van der Doelen","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826022153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826022153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:37:18Z","timestamp":1782272238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826022153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":7,"alternative-id":["S0302283826022153"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.06.001","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men with Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}